NoticiasCon ayuda de IA

NeuroBo Transforms into MetaVia Inc.

NeuroBo becomes MetaVia, focusing on MASH and obesity therapies with key trials nearing milestone results.

Por Mrudula Kulkarni

Editor Gerente - Pharma Now

19 nov 2024Updated Jun 26, 2025 · 2 min de lectura

Compartir Añadir como fuente preferida

NeuroBo Transforms into MetaVia Inc. — https://www.neurobopharma.com/

Reportaje con ayuda de IA

Reviewed by Mrudula Kulkarni, Editor Gerente - Pharma Now

NeuroBo Pharmaceuticals, soon to be renamed MetaVia Inc., is realigning its corporate identity to focus on cardiometabolic disease therapies, with the transition effective November 29, 2024. Trading on Nasdaq under the new ticker MTVA, MetaVia aims to highlight its innovative pipeline, including:

DA-1241: A GPR119 agonist for metabolic dysfunction-associated steatohepatitis (MASH), with Phase 2a trial data expected in December 2024.
DA-1726: A dual OXM analog for obesity, with top-line Phase 1 MAD cohort results anticipated in Q1 2025.

MetaVia emphasizes its strong funding foundation and ambition to deliver next-generation treatments.

TemasNews

Written by

Mrudula Kulkarni

Editor Gerente - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.